The National MDS Study
Welcome
The mission of The National MDS Study (ClinicalTrials.gov Identifier: NCT02775383) is to build a resource that scientists can use to learn more about a group of rare bone marrow diseases called myelodysplastic syndromes (MDS). The National MDS Study will enable scientists to conduct research that will improve the way MDS is diagnosed and how it is treated. The study will also enable scientists, patients, and their families to better understand what to expect when a patient is diagnosed with MDS. The National MDS Study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the National Cancer Institute (NCI).
MDS Predictive Tool
The MDS study has developed a 2-stage diagnostic classifier based on mutations in 18 genes that can be applied alone or in combination with a morphologic review to predict diagnosis of myeloid malignancy and MDS. Please click the link below to access our online predictive tool which is referenced in our Blood Advances publication (DeZern et. al., 2023).
Interactive Inventory Browser
The MDS Interactive Inventory Browser is a dynamic publicly accessible database query tool that allows one to identify cohorts of interest from our study and perform research feasibility analysis based on the availability of clinical, lab, and genetic data. If you do not have a login, a “Registration Form” needs to be completed and submitted. Once an account has been approved an email will be sent with initial log in instructions.
Should I join a clinical trial?
If you are considering joining a clinical trial such as the National MDS Natural History Study, we recommend first learning about the trial's goals and how involvement in the study may benefit you and/or society. Please remember to always consult with your physician to ensure that you meet study criteria and that your participation in the study will not negatively impact any current treatment or underlying conditions. If you are interested in additional general information about clinical trials, please click here to access a March 2023 article published in The Washington Post's personal health section, Well+Being, where MDS Study Chair, Dr.Mikkael Sekeres , offers expert advice.